US7625884 — Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Method of Use · Assigned to Salix Pharmaceuticals Ltd · Expires 2026-08-24 · 0y remaining
What this patent protects
This patent protects a method of increasing the bioavailability of balsalazide by taking an oral dosage form with food.
USPTO Abstract
A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-141 |
— | balsalazide-disodium |
U-1229 |
— | balsalazide-disodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.